{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:17:21Z","timestamp":1781669841284,"version":"3.54.5"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babes University of Medicine and Pharmacy Timisoara"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background and Objectives: Ovarian carcinosarcoma (OCS) is a rare gynecologic malignancy defined by both epithelial and mesenchymal components, generally associated with advanced clinical stage and poor outcomes. We present a 66-year-old patient initially presenting with right iliac vein thrombosis, ultimately diagnosed with OCS, and place these findings in context with a focused literature review from 2000 through to 2024. Methods: A comprehensive account of the patient\u2019s clinical course\u2014spanning diagnostic imaging, surgical pathology, neoadjuvant chemotherapy, and interval debulking\u2014was combined with a review of the current data on OCS pathogenesis, treatment protocols, and outcomes. Results: The patient\u2019s tumor showed predominantly sarcomatous histology (approximately 90%) with high-grade serous features, responded to platinum\/taxane chemotherapy, and was resected to no visible residual disease. The updated literature indicates that the majority of OCS cases present at advanced stages (often exceeding 60%), with suboptimal cytoreduction closely tied to worse prognosis. Up to 64% of tumors may harbor homologous recombination deficiency, offering a rationale for PARP inhibitor therapy; nonetheless, five-year survival rarely surpasses 45% in most series. Conclusions: Despite its aggressive course, optimal debulking surgery plus platinum-based chemotherapy remain central in treating OCS. Emerging molecular insights highlight homologous recombination deficiency and BRCA mutations as potential therapeutic targets. Multidisciplinary care and future prospective studies are key to improving long-term outcomes in this challenging malignancy.<\/jats:p>","DOI":"10.3390\/diseases13060163","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:04:28Z","timestamp":1747897468000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report"],"prefix":"10.3390","volume":"13","author":[{"given":"Alexandra","family":"Nienhaus","sequence":"first","affiliation":[{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Department of Obstetrics and Gynaecology \u201cAugusta Krankenanstalt\u201d Bochum, Bergstr. 26, 44807 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2714","authenticated-orcid":false,"given":"Elena","family":"Bernad","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Center for Laparoscopy, Laparoscopic Surgery and In Vitro Fertilization, \u201cVictor Babes\u201d University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.annonc.a059312","article-title":"Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients","volume":"6","author":"Chang","year":"1995","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2013.07.097","article-title":"Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: A SEER analysis","volume":"131","author":"Diver","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s11864-023-01138-4","article-title":"Frontiers of Ovarian Carcinosarcoma","volume":"24","author":"Ismail","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.20256","article-title":"Carcinosarcoma of the ovary: 19 years of prospective data from a single center","volume":"100","author":"Brown","year":"2004","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2004.01.007","article-title":"Gynecologic Oncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study","volume":"93","author":"Blessing","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Brackmann, M., Stasenko, M., Uppal, S., Erba, J., Reynolds, R.K., and McLean, K. (2018). Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: A single institution case series and review of the literature. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4082-6"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2559.2000.01015.x","article-title":"Prognostic factors in ovarian carcinosarcoma: A clinicopathological and immunohistochemical analysis of 23 cases","volume":"37","author":"Ariyoshi","year":"2000","journal-title":"Histopathology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2013.06.034","article-title":"Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome","volume":"131","author":"George","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","article-title":"Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group Study","volume":"16","author":"Markman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zheng, J., Tang, C., Liu, P., and Hao, H. (2023). Carcinosarcoma of the ovary: A case report and literature review. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1278300"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2016.11.042","article-title":"Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma","volume":"144","author":"Matsuo","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Damia, G., and Broggini, M. (2019). Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers, 11.","DOI":"10.3390\/cancers11010119"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2007.09.003","article-title":"Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum","volume":"108","author":"Cicin","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2018.12.006","article-title":"Ovarian carcinosarcoma: Current developments and future perspectives","volume":"134","author":"Boussios","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0090-8258(84)90039-8","article-title":"A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: A Gynecologic Oncology Group study","volume":"18","author":"Morrow","year":"1984","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Koshiyama, M., Matsumura, N., and Konishi, I. (2014). Recent concepts of ovarian carcinogenesis: Type I and type II. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/934261"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2011.12.418","article-title":"Carcinosarcoma of the ovary: A review of the literature","volume":"125","author":"Birrer","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/oxfordjournals.aje.a115414","article-title":"Re: \u201cFamilial ovarian cancer: A population-based case-control study\u201d","volume":"130","author":"Harlow","year":"1989","journal-title":"Am. J. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13048-020-0617-y","article-title":"A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"13","author":"Nagao","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1525-1438.2006.00760.x","article-title":"Current management of ovarian carcinosarcoma","volume":"17","author":"Mano","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fan Liang, F., Shi, Y., Chen, Y., Tao, X., and Ding, J. (2024). Clinicopathological and molecular features of tubo-ovarian carcinosarcomas: A series of 51 cases. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1427154"},{"key":"ref_22","first-page":"10808925","article-title":"Successful treatment of stage IVB ovarian carcinosarcoma with PARP inhibitor: A case report","volume":"45","author":"Abel","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_23","first-page":"e11521086","article-title":"Ovarian carcinosarcoma with lung metastasis characterized by persistent fever: A case report and literature review","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine"},{"key":"ref_24","first-page":"21","article-title":"Ovarian carcinosarcoma of heterologous type occurring in an endometriotic cyst with 3-year recurrence-free survival: A case report and literature review","volume":"14","author":"Sumino","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_25","first-page":"11305719","article-title":"Sigmoido-ovarian fistula complicating ovarian carcinosarcoma: A case report","volume":"107","author":"Siala","year":"2024","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_26","first-page":"e11363008","article-title":"Initial presentation of ovarian carcinosarcoma with non-islet cell tumor hypoglycemia: A case report","volume":"16","author":"Elemian","year":"2024","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16134","DOI":"10.1111\/jog.16134","article-title":"A case of ovarian carcinosarcoma with germline BRCA2 pathogenic variant","volume":"50","author":"Yoriki","year":"2024","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.3802\/jgo.2024.35.e31","article-title":"Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea","volume":"35","author":"Ha","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100840","DOI":"10.1016\/j.gore.2021.100840","article-title":"Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma","volume":"37","author":"Hunt","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13048-020-00728-2","article-title":"Primitive ovarian carcinosarcoma: A clinical and radiological analysis of five cases","volume":"13","author":"Xu","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"McFarlane, I., Porter, J.M., Brownsell, E., Ghaoui, N., Connolly, K.C., Herrington, C.S., and Hollis, R.L. (2024). Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1399979"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s10637-024-01448-w","article-title":"A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed\/refractory B-cell lymphomas","volume":"42","author":"Sangha","year":"2024","journal-title":"Invest. New Drugs."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1080\/21655979.2021.2000225","article-title":"Expression of Cyclin D1 gene in ovarian cancer and effect of silencing its expression on ovarian cancer cells based on the Oncomine database","volume":"12","author":"Quan","year":"2021","journal-title":"Bioengineered"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/6\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:38:11Z","timestamp":1760031491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/6\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["diseases13060163"],"URL":"https:\/\/doi.org\/10.3390\/diseases13060163","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}